Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LevoTako Trial
2022-003628-42Phase 3Active
- Sponsor
- Medical University of Gdańsk
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Takotsubo cardiomyopathy (TCM) comparing Simdax with Placebo (2 arms). Primary endpoint: Left ventricular ejection fraction improvement. Started Feb 2023; status: active.
02
Drugs
levosimendan
03
Conditions
Takotsubo cardiomyopathy (TCM)
Beyond the preview
Go deeper on 2022-003628-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003628-42.